Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025)

Innate Pharma (IPHA) has reported Non-Current Deffered Revenue for 9 consecutive years, with -$3.6 million the latest figure, recorded in Q2 2025.

• Quarterly Non-Current Deffered Revenue fell 107.62% year-over-year to -$3.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$3.6 million (down 107.62% YoY) and the FY2024 annual result came in at $3.2 million, down 38.83% from the prior year.
• Non-Current Deffered Revenue eased to -$3.6 million in Q2 2025 per IPHA's latest filing, from $3.2 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for IPHA reached as high as $47.7 million in Q2 2024 and fell as low as -$43.3 million in Q2 2021.
• A 5-year average of $1.6 million and a median of $3.2 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue soared 480.09% — and 2025, when it sank 107.62%.
• Year by year, Non-Current Deffered Revenue stood at $28.9 million in 2021, then sank by 68.83% to $9.0 million in 2022, then slumped by 41.7% to $5.3 million in 2023, then plunged by 38.83% to $3.2 million in 2024, then slumped by 212.96% to -$3.6 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered -$3.6 million, $3.2 million, and $47.7 million for Q2 2025, Q4 2024, and Q2 2024 respectively.